Houston, Texas-based FGH Biotech said it entered a license agreement with Kyoto University (KU) and Tokyo University of Agriculture and Technology (TUAT) that gives FGH “access to ground-breaking Vitamin D based technologies to address metabolic disorders and cancer.”
FGH said the agreement provides it with “an exclusive worldwide license to patents and technology for the development and commercialization of Vitamin D and its derivatives for therapeutic and nutritional use.”
Financial details of the license agreement were not disclosed.
FGH said it is a leader in “small molecules targeting transcription factors that serve as the master regulatory switch for fat production, known as sterol regulatory element-binding proteins (SREBP).”
FGH said its patented drug candidates called “Fatostatins” directly target this pathway.
“Research conducted at KU by FGH co-founder Dr. Motonari Uesugi, deputy director of the university’s institute for integrated Cell-Material Sciences (iCeMS) and Dr. Kazuo Nagasawa at TUAT’s faculty of engineering, has demonstrated a novel mechanism of action by which Vitamin D and specific analogs can regulate SREBP pathways as recently published in the February 16, 2017 issue of Cell Chemical Biology,” said FGH.
“Growing evidence has supported an association of Vitamin D levels and metabolic disease, including fatty liver.
“Importantly, this publication now reveals the molecular mechanism demonstrating how vitamin D influences fat and energy metabolism.”